Altre lingue uniQure N.V.

Azioni

QURE

NL0010696654

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 09/07/2024			Variaz. 5gg	Var. 1 gen.
6,67 ^USD	+76,46%		+50,06%	-1,48%

09/07	Il candidato farmaco per la malattia di Huntington di UniQure rallenta la progressione della malattia negli studi aggiornati -- Le azioni salgono prima della campanella	MT
09/07	Transcript : UniQure N.V. - Special Call

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

UniQure N : July 2024 Huntington's Disease Program Update AMT-130	09/07
UniQure Huntington's Drug Candidate Slows Disease Progression in Updated Trials -- Shares Rise Pre-Bell	09/07
UniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease	09/07
Sector Update: Health Care Stocks Mixed Premarket Monday	01/07
UniQure's Commercial Gene Therapy Operations to be Acquired by Genezen	01/07
Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA	01/07
UniQure Announces Sale of Commercial Manufacturing Facility to Genezen	01/07
Genezen Laboratories, Inc. entered into an agreement to acquire Global Manufacturing Facility in Lexington, Massachusetts from uniQure N.V..	01/07
UniQure Shares Rise After US FDA Grants Regenerative Medicine Advanced Designation for Huntington's Treatment	03/06
UniQure's AMT-130 Gets FDA RMAT Designation in Huntington's Disease	03/06
UniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease	03/06
UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Earnings Flash (QURE) UNIQURE Reports Q1 Revenue $8.5M	07/05
UniQure: Q1 Earnings Snapshot	07/05
UniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress	07/05
Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director	12/04
UniQure N.V.(NasdaqGS:QURE) dropped from S&P Biotechnology Select Industry Index	18/03
UniQure N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
UniQure Announces 2023 Financial Results and Highlights Recent Company Progress	28/02
UniQure N : December 2023 Huntington's Disease Program Update AMT-130	19/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue uniQure N.V.

Azioni

QURE

NL0010696654

Altre lingue

Filtri